Investigation Into the Effects of Blood Glucose Levels Upon Eating Behavior in Lean and Obese Non-diabetic and Diabetic Subjects
8 de abril de 2022 actualizado por: Yale University
To investigate whether the daily glucose profiles as assessed by continuous glucose monitoring for 1 week of normal weight and obese individuals relate to hunger levels and food intake.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Descripción detallada
To evaluate the effect of blood glucose levels on eating behavior in a population of patients with diabetes in a free-living environment; the investigators plan to study lean healthy control subjects (BMI <25 kg/m2) and obese non-diabetic subjects (BMI > 30 kg/m2).
The participants who qualify will be invited to use the CGMS (DEXCOM G4 Platinum) for up to 7 days. On the visit for placement of the CGMS: 1) the participants will be explained by one of the study physicians how to use a glucometer (FreeStyle or Accu-Check), 2) they will have the CGMS inserted under the skin, and 3) they will be instructed how to fill up the food log (informational brochures are available at the end of the protocol. On the second visit (up to 7 days after the initial visit) the CGMS will be removed from the skin and the glucose meter and food log will be returned to the investigators.
When this study was initially designed, it incorporated 2 additional arms in the study: T1DM and obese T2DM patients. These patients were never recruited for the study.
Tipo de estudio
Intervencionista
Inscripción (Actual)
31
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06520
- Yale University School of Medicine
-
New Haven, Connecticut, Estados Unidos, 06519-1362
- Yale New Haven Hospital
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años a 65 años (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
Sí
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- A1c < 10.5 %
Exclusion Criteria:
- BMI <18 (no upper limit),
- Creatinine > 1.5 mg/dL,
- Hgb < 10 mg/dL,
- ALT > 2.5 X ULN,
- untreated thyroid disease,
- uncontrolled hypertension,
- known neurological disorders,
- untreated psychiatric disorders,
- use of antidepressants and psychiatric medications,
- use of weight loss medications in the 6 months prior to the study,
- malignancy,
- smoking,
- current or recent steroid use in last 3 months,
- history of current illicit drug use;
- for women: pregnancy, or breastfeeding.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Diagnóstico
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Lean Healthy Control
(BMI <25 kg/m2)
|
The CGMS consists of 3 parts: sensor, transmitter and monitor.
The small sensor measures the glucose levels from the interstitial tissue.
The transmitter is attached on top of the sensor and connects wirelessly to the monitor.
The sensor is sterile and comes in an unopened package.
It has a plastic wire-like tip that is placed under the skin and continuously measures the glucose levels.
One of the study physicians will insert the CGMS wire-like tip under the volunteer's skin with the use of the DEXCOM sensor insertion kit.
The transmitter is snapped to the sensor pod and the sensor/transmitter unit will be attached to the skin with an adhesive patch.
The monitor is the size of a small hand-held device with a digital screen that displays a graph showing the glucose levels from the previous 4-24 hours.
Otros nombres:
The Food Record will ask about amount and type of food consumed throughout the day.
The participants will also register how hungry they are before the meal and how full they feel after they ate, and type and duration of physical activity
|
|
Comparador activo: Obese non-diabetic subject
BMI > 30 kg/m2
|
The CGMS consists of 3 parts: sensor, transmitter and monitor.
The small sensor measures the glucose levels from the interstitial tissue.
The transmitter is attached on top of the sensor and connects wirelessly to the monitor.
The sensor is sterile and comes in an unopened package.
It has a plastic wire-like tip that is placed under the skin and continuously measures the glucose levels.
One of the study physicians will insert the CGMS wire-like tip under the volunteer's skin with the use of the DEXCOM sensor insertion kit.
The transmitter is snapped to the sensor pod and the sensor/transmitter unit will be attached to the skin with an adhesive patch.
The monitor is the size of a small hand-held device with a digital screen that displays a graph showing the glucose levels from the previous 4-24 hours.
Otros nombres:
The Food Record will ask about amount and type of food consumed throughout the day.
The participants will also register how hungry they are before the meal and how full they feel after they ate, and type and duration of physical activity
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Rate of Changing Glucose Level
Periodo de tiempo: 3-5 days
|
The CGM sensor measures the glucose levels from the interstitial tissue.
Presented is the rate of changing glucose level (mg/dl/min).
|
3-5 days
|
|
Glucose Peak
Periodo de tiempo: 3-5 days
|
The CGM sensor measures the glucose levels from the interstitial tissue.
Presented is the glucose peak (mg/dl).
|
3-5 days
|
|
Glucose Nadir
Periodo de tiempo: 3-5 days
|
The CGM sensor measures the glucose levels from the interstitial tissue.
Presented is the glucose nadir (mg/dl).
|
3-5 days
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Difference in Glucose Peak and Nadir
Periodo de tiempo: 3-5 days
|
The CGM sensor measures the glucose levels from the interstitial tissue.
Presented is the difference in glucose peak and nadir (mg/dl).
|
3-5 days
|
|
Average Daily Hunger Rating
Periodo de tiempo: 3-5 days
|
Average daily hunger was measured using a self-report scale.
Hunger is measured on a scale from 1-10. 10 is the most hungry, 1 is the least hungry.
|
3-5 days
|
|
Nutirion Intake: Energy
Periodo de tiempo: 3-5 days
|
Data were collected through food journals.
Energy and macronutrient composition were calculated from self-reported food records based on Nutrition Data System for Research (NDS-R).
Presented is the average daily energy intake (kcal/day).
|
3-5 days
|
|
Nutirion Intake: Carbohydrate
Periodo de tiempo: 3-5 days
|
Data were collected through food journals.
Energy and macronutrient composition were calculated from self-reported food records based on Nutrition Data System for Research (NDS-R).
Presented is the average daily carbohydrate intake (g/day).
|
3-5 days
|
|
Nutirion Intake: Fat
Periodo de tiempo: 3-5 days
|
Data were collected through food journals.
Energy and macronutrient composition were calculated from self-reported food records based on Nutrition Data System for Research (NDS-R).
Presented is the average daily fat intake (g/day).
|
3-5 days
|
|
Nutirion Intake: Protein
Periodo de tiempo: 3-5 days
|
Data were collected through food journals.
Energy and macronutrient composition were calculated from self-reported food records based on Nutrition Data System for Research (NDS-R).
Presented is the average daily protein intake (g/day).
|
3-5 days
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Investigador principal: Renata Belfort De Aguiar, MD, PhD, Yale School of Medicine
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
1 de febrero de 2016
Finalización primaria (Actual)
14 de diciembre de 2017
Finalización del estudio (Actual)
14 de diciembre de 2017
Fechas de registro del estudio
Enviado por primera vez
1 de febrero de 2016
Primero enviado que cumplió con los criterios de control de calidad
2 de febrero de 2016
Publicado por primera vez (Estimar)
3 de febrero de 2016
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
5 de mayo de 2022
Última actualización enviada que cumplió con los criterios de control de calidad
8 de abril de 2022
Última verificación
1 de abril de 2022
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- 1503015469
- 1K23DK098286-01A1 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
NO
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Continuous Glucose Monitoring System (CGMS)
-
Dartmouth-Hitchcock Medical CenterRetirado